B1QB Stock Overview
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
NRx Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.54 |
52 Week High | US$0.66 |
52 Week Low | US$0.42 |
Beta | 0.99 |
1 Month Change | n/a |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -97.19% |
Recent News & Updates
Recent updates
Shareholder Returns
B1QB | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 26.2% | 2.3% | 1.9% |
1Y | n/a | -25.9% | 7.3% |
Return vs Industry: Insufficient data to determine how B1QB performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how B1QB performed against the German Market.
Price Volatility
B1QB volatility | |
---|---|
B1QB Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 6.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: B1QB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine B1QB's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | n/a | Steve Willard | https://www.nrxpharma.com |
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression. The company has a partnership with Alvogen and Lotus to develop and commercialize NRX-101 for the suicidal bipolar depression treatment, as well as an agreement with Nephron Pharmaceuticals, Inc. to develop ketamine.
NRx Pharmaceuticals, Inc. Fundamentals Summary
B1QB fundamental statistics | |
---|---|
Market cap | €43.72m |
Earnings (TTM) | -€33.29m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs B1QB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
B1QB income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$36.06m |
Earnings | -US$36.06m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Mar 28, 2024
Earnings per share (EPS) | -0.39 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -162.0% |
How did B1QB perform over the long term?
See historical performance and comparison